<DOC>
	<DOCNO>NCT00643929</DOCNO>
	<brief_summary>A long term observational ocular safety study adult receive study medication ( either active drug placebo ) phase II III clinical study evaluate eltrombopag . The study follow subject 2.5 year follow last ocular assessment prior treatment study ( regardless therapeutic indication ) describe long-term ocular safety respect change lenses time subject .</brief_summary>
	<brief_title>LENS - Long-term Eltrombopag Observational Study</brief_title>
	<detailed_description />
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Subjects eligible enrolment study previously participate eltrombopag study , either phase II III , meet follow criterion : Subject sign dated write informed consent study . Subject previously participate study evaluate eltrombopag , either phase II III , must receive least one dose study medication ( either active drug placebo ) . This exclude subject phase I study ( See Section 5.1 ) . The prescribed followup ophthalmic assessment 6 month post end treatment complete specify protocol previous study . Subject able understand comply protocol requirement instruction . Subjects meet follow criterion must enrol study : Subject receive surgery cataract aphakic bilaterally pseudophakic . In country ( i.e . France ) , subject neither affiliated beneficiary social security category .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>thrombopoietin receptor agonist</keyword>
	<keyword>ocular safety</keyword>
	<keyword>HCV</keyword>
	<keyword>SB-497115-GR</keyword>
	<keyword>CIT</keyword>
	<keyword>ITP</keyword>
	<keyword>cataract</keyword>
	<keyword>eltrombopag olamine</keyword>
	<keyword>lens opacity</keyword>
</DOC>